Search Results

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate agent.

Sirnaomics Ltd., a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023.

Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the Company published a research article with NAR Cancer.

Sirnaomics Ltd. will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT Congress, which took place in Boston, USA from March 13-14, 2024.

Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, announced the promotion of Dr. Francois Lebel, M.D., to Chief Medical Officer.

Sirnaomics Ltd. presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction’s positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, together with its subsidiaries, the “Group” or “Sirnaomics”) reported that a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference, which took place October 22–25 in Las Vegas.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, has announced its interim results for the six months ended 30 June 2023.

Sirnaomics Ltd. (the “Company”, Stock Code: 2257, together with its subsidiaries, the “Group” or “Sirnaomics”), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced the successful completion of Cohort 1 in an ongoing Phase I clinical trial of STP122G, targeting Factor XI as a novel form of anticoagulation.